

3427 Hillview Avenue, Suite 200
Palo Alto, CA 94304



KaloBios Elects Denise M. Gilbert, Ph.D. to the Board of Directors

PALO ALTO, California, January 28, 2008 – KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced the election of Denise M. Gilbert, Ph.D. to the KaloBios Board of Directors.

Dr. Gilbert, currently an independent consultant and strategic advisor to life science companies, previously served as Chief Executive Officer of Entigen Corporation, a private life science information technology company. In addition, Dr. Gilbert has served as Chief Financial Officer of two public life science companies, Incyte Pharmaceuticals Inc. and Affymax NV. Dr. Gilbert started her career in biotechnology in the mid 1980's, first in venture capital and then as a senior biotechnology analyst with Smith Barney Harris & Upham and Montgomery Securities. Dr. Gilbert holds a B.A. from Cornell University and a Ph.D. in Cell and Development Biology from Harvard University.

“We are very pleased to welcome Denise to the KaloBios Board,” said David Pritchard, CEO of KaloBios. “Her many years of experience in growing both private and public companies, as well as her extensive knowledge of life sciences investment will serve KaloBios well as we continue to build our therapeutic monoclonal antibody business and capitalize on the unique capabilities of our Humaneering™ platform.”

“I am looking forward to working with KaloBios,” Dr. Gilbert commented. “The company has promising antibody technology and a portfolio of products addressing large market opportunities.”

About KaloBios

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its proprietary platform technology to develop first or best-in-class human antibody therapeutics. It currently has two programs that have completed Phase 1 studies and are entering Phase 1/2 studies; KB001 is an anti-infective for *Pseudomonas aeruginosa* infections to be tested in cystic fibrosis and intensive care patients on a ventilator, and KB002 is an anti-inflammatory in a study for rheumatoid arthritis and entering a study for persistent asthma patients. The company's Humaneering™ technology offers advantages over other methods of human antibody creation in terms of immunogenicity, potency, and manufacturing yields. For more information, visit www.kalobios.com.

Contact:

David W. Pritchard
President and CEO
KaloBios Pharmaceuticals, Inc.
(650) 843-1897 x 300

Media Contact:

Joan E. Kureczka
Kureczka/Martin Associates
(415) 821-2413
Jkureczka@comcast.n